Compare Globus Medical Inc. Class A Common Stock (GMED) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Ryanair Holdings plc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Ryanair Holdings plc trades at $51.99 (market cap $26.41B). The key difference: Ryanair Holdings plc is far larger — about 2.6× Globus Medical Inc. Class A Common Stock's market cap, and Ryanair Holdings plc pays a 1.69% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Ryanair Holdings plc for 72 Days on average.
| GMED | RYAAY | |
|---|---|---|
Market Cap | $10.25B | $26.41B |
Volume | 1,108,124 | 2,266,391 |
Sector | Health | Industrials |
52-Week High | $96.82 | $73.82 |
52-Week Low | $58.33 | $51.33 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $9.76B | $23.47B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
RYAAY trades at $51.33, down 3.15% amid bearish technical signals despite strong fundamentals. The stock shows robust profitability with 12.13% net margins and attractive valuation at 13.23 P/E. Recent earnings performance has been mixed with Q1 2026 beating expectations but Q2 2026 missing. Technical indicators signal bearish momentum with oversold RSI conditions, while analyst consensus remains positive with 64.71% buy ratings.
The outlook balances strong operational performance against near-term headwinds including fuel cost volatility and Boeing MAX 10 certification delays. Revenue growth trajectory and market share gains support long-term potential, though elevated oil prices and competitive pressures present significant risks. Current valuation levels offer entry opportunity for patient investors despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
